By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
BELBUCA58.26M27.83%
Xtampza Extended-release (ER)50.48M24.11%
Jornay PM41.8M19.97%
Nucynta Immediate-release (IR)31.99M15.28%
Nucynta Extended-release (ER)22.81M10.90%
Symproic4.03M1.92%
View all
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States631.45M100.00%